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Simple Summary: Liver stem cells and activated macrophages have been implicated as contributors 
to liver cancer; hence, reducing their abundance is a potential avenue for therapy. In this article, we 
demonstrate that Maraviroc, a drug approved for human use, reduces the liver stem cell response 
and macrophage activation in a mouse model of liver cancer. These findings underline the preven-
tive potential of this drug in liver cancer, a deadly disease for which there are few effective treat-
ments. 
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Abstract: Maraviroc (MVC), a CCR5 antagonist, reduces liver fibrosis, injury and tumour burden in 
mice fed a hepatocarcinogenic diet, suggesting it has potential as a cancer therapeutic. We investi-
gated the effect of MVC on liver progenitor cells (LPCs) and macrophages as both have a role in 
hepatocarcinogenesis. Mice were fed the hepatocarcinogenic choline-deficient, ethionine-supple-
mented diet (CDE) ± MVC, and immunohistochemistry, RNA and protein expression were used to 
determine LPC and macrophage abundance, migration and related molecular mechanisms. MVC 
reduced LPC numbers in CDE mice by 54%, with a smaller reduction seen in macrophages. Tran-
script and protein abundance of LPC-associated markers correlated with this reduction. The CDE 
diet activated phosphorylation of AKT and STAT3 and was inhibited by MVC. LPCs did not express 
Ccr5 in our model; in contrast, macrophages expressed high levels of this receptor, suggesting the 
effect of MVC is mediated by targeting macrophages. MVC reduced CD45+ cells and macrophage 
migration in liver and blocked the CDE-induced transition of liver macrophages from an M1- to M2-
tumour-associated macrophage (TAM) phenotype. These findings suggest MVC has potential as a 
re-purposed therapeutic agent for treating chronic liver diseases where M2-TAM and LPC numbers 
are increased, and the incidence of HCC is enhanced. 




Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is a leading 
cause of cancer mortality worldwide, and its incidence is increasing in many regions [1]. 
HCC predominantly arises in the context of chronic inflammatory conditions, most nota-
bly, viral hepatitis B (HBV) and C (HCV) [1]. Although infectious agents are the primary 
cause of liver cancer worldwide, the incidence in Western countries is rising due to the 
obesity epidemic and non-alcoholic steatohepatitis [2]. 
Liver tumourigenesis generally arises from continuous parenchymal damage in 
which hepatocyte cell death drives compensatory proliferation. Within this chronic in-
flammation context, liver mutations and epigenetic changes accumulate and eventually 
transform hepatocytes into malignant cells. An understanding of how tissue-intrinsic pro-
cesses determine the balance of cell proliferation and cell death and how chronic inflam-
mation regulates these processes and causes liver cancer is required to develop effective 
therapeutics to treat and prevent HCC. 
In many settings of chronic liver disease, the regenerative ability of hepatocytes is 
compromised invoking an alternative path involving liver progenitor cells (LPCs) [3]. 
LPCs have been identified in HCV infection [4], alcoholic liver disease, HBV infection and 
genetic hemochromatosis, and importantly, their numbers correlate with disease severity 
[5]. Furthermore, LPC markers have accurately predicted short-term mortality in patients 
with alcoholic hepatitis and are correlated with poor prognosis of HCC [6,7]. Collectively, 
these findings make a strong case for LPCs as a cancer stem cell candidate in hepatocar-
cinogenesis. 
Further evidence of the tumourigenic potential of LPCs has been demonstrated by 
the tumourigenic transformation of LPCs in vitro by forced expression of oncogenes [8]. 
MYC over-expression in the liver induces HCC, but when the promoter regulating its ex-
pression is switched off, LPC-like cells differentiate into hepatocytes and cholangiocytes 
[9] suggesting they were the source of the cancer. Moreover, extinguishing p53 expression 
in an LPC line transforms them into hepatoma cells [10], and tumourigenic LPCs can be 
isolated from p53 null mice placed on a choline-deficient, ethionine-supplemented (CDE) 
diet [11]. Collectively these findings suggest that LPCs are a potential source of HCC. 
Tumour-associated macrophages (TAMs) are a critical component of the tumour mi-
croenvironment (TME). TAMs are macrophages present in close proximity to tumour cells 
Cancers 2021, 13, 4935 3 of 21 
 
 
and play important roles in influencing the host immune response to cancer. Macro-
phages, like many other immune effector cells, exist as multiple subtypes with differing 
expression patterns, surface markers and secretable factors. Generally, resistance to intra-
cellular pathogens and tumours (Th1-driven responses) are mediated by M1-polarised 
macrophages, whereas M2-polarised macrophages mediate resistance to parasites, immu-
noregulation, tissue repair and immuno-tolerance to tumours. When present in high num-
bers, TAMs are associated with poor survival, the promotion of metastasis, angiogenesis 
and invasion into nearby tissues and vasculature across many cancer types [12–14]. 
Chemokines and their receptors play crucial roles in the initiation and maintenance 
of inflammation and fibrosis [15,16], as well as in chronic inflammation that leads to tu-
mourigenesis [15]. CCR5, a member of the G-protein-coupled receptor superfamily, is a 
cognate receptor for several inflammatory chemokines including CCL3 (macrophage in-
flammatory protein 1 alpha; MIP 1α), CCL4 (MIP-1β) and CCL5 [16]. CCR5 plays a central 
role in many events related to liver matrix remodelling as a result of its expression in 
hepatic stellate cells (HSCs), and there is evidence of interaction between HSCs and LPCs, 
resulting in LPC proliferation and HSC activation [17]. Accordingly, there are high levels 
of both CCR5 and its ligand, CCL5, in patients with chronic liver disease and fibrosis [18]. 
T cells, Kupffer cells [19], HSCs [20] and LPCs [21] all express CCR5 in injured liver. Gene 
targeting or the use of a potent antagonist for the murine CCR5 receptor results in a sig-
nificant reduction of liver fibrosis [18]; however, the exact role of CCR5, and which CCR5-
expressing cell type is involved in HCC, remains unclear.  
Since CCR5 is a main entry point for the human immunodeficiency virus (HIV), sev-
eral inhibitors have been developed for its use to treat HIV by reducing viral load; the 
most common being Maraviroc (MVC) [22]. It has been reported that MVC treatment re-
duces fibrosis progression in HIV/HCV co-infected patients with CCR5 tropism [23]. 
Our previous studies showed the importance of inflammation in initiating the LPC 
response; it is attenuated in IL6 and TNF receptor knockout (KO) mice subjected to a CDE 
diet, with a commensurate decrease in HCC incidence [24]. The LPC response is also di-
minished in lymphotoxin beta KO mice [25] and Fn14 KO mice in which tumour necrosis 
factor-like weak inducer of apoptosis (TWEAK) signalling is attenuated and both inflam-
mation and the LPC response are suppressed [26]. Finally, recruitment of inflammatory 
monocytes enhances inflammation and promotes initiation of LPC proliferation [27]. 
Our previous study demonstrated the efficacy of MVC in reducing disease progres-
sion and increasing survival rates in a mouse model of CDE-diet-induced HCC [28]. We 
showed MVC significantly reduced mortality, markers of liver injury, apoptosis, prolifer-
ation, expression levels of chemokines, fibrosis and hepatic tumour load [28]. This study 
sought a mechanistic explanation for the anti-hepatocarcinogenic effect of MVC. We 
demonstrated that through its anti-inflammatory effect, MVC attenuates the LPC re-
sponse, coinciding with a reduction in HCC development. We concluded that MVC, an 
approved, well-tolerated and characterised drug, may be re-purposed as a preventative 
treatment for HCC. 
2. Materials and Methods 
2.1. Animals and Animal Model 
A total of 61 WT C57BL/6J male mice were purchased from Charles River (Barcelona, 
Spain). All animals had unrestricted access to food and water during the study. When the 
animals were approximately 5 weeks old, they were randomly assigned to one of 4 diet 
groups: (i) Control, (ii) MVC, (iii) CDE diet and (iv) CDE + MVC. Control group mice were 
fed a choline-sufficient diet (MP Biomedicals, , Illkirch, France, SKU 02960414-CF) and tap 
water, n = 10. Mice in the MVC group received the Control group diet, supplemented with 
300 mg/L Maraviroc (MVC, Pfizer, New York, NY, USA) in the drinking water, n = 11. For 
the correct MVC dose in mice, an interspecies allometric scaling factor of 12.3 was used, 
resulting in a dose equivalent to a human dose of 300 mg/day [29]. The CDE-diet-treated 
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animals received the choline-deficient diet (MP Biomedicals, SKU: 02960210-CF,), and 
0.165% ethionine (Sigma, St Louis, MO, USA) supplemented the drinking water, n = 20. 
Finally, the CDE + MVC-treated animals were fed with the same diet as the CDE group 
but received MVC in the drinking water at the same concentration as the MVC group, n = 
20. All surviving animals were sacrificed at week 16. Tissue pieces were fixed in buffered 
formalin (10%) for histological analysis or snap-frozen in liquid nitrogen for biochemical 
and molecular analyses. 
2.2. Serum Levels of Alanine Amino Transferase 
Blood samples were collected from all surviving animals on week 16 during final 
sacrifice. Levels of liver damage markers (transaminases) were measured using standard 
assays in an automatic biochemical analyser (Cobas C711, Roche, Madrid, Spain). 
2.3. Immunohistochemical Staining 
Immunohistological staining was carried out on 5 µm thick formalin-fixed tissue sec-
tions. Antigens were retrieved with 40 µg/mL Proteinase K (Dako, North Sydney, Aus-
tralia) for PanCK and SOX9, 20 µg/mL Proteinase K for F4/80 and EnVision FLEX target 
retrieval solution (Dako, Cat. GV805) for CD45 immunohistochemistry. Endogenous pe-
roxidases were blocked with 3% H2O2. Sections were then incubated with DAKO Serum-
Free Protein Block (Dako, Cat. X0909), prior to application of PanCK, SOX9 or F4/80 or 
CD45 (Dako, Cat. Z0622 at 1/400, Merck, Darmstadt, Germany, Cat. AB5535 at 1/500 or 
Bio-Rad, Gladesville, Australia, Cat. MCA497 at 1/100, respectively) overnight at 4 °C. 
Other sections were incubated with CD45 monoclonal antibody (BD Biosciences, San Di-
ego, CA, USA, Cat. 550539; 1:10 dilution) overnight at room temperature. PanCK and 
SOX9 were detected with the LSAB+ kit (Dako, Cat. K5001). F4/80 and CD45 were detected 
with biotinylated anti-rat IgG (Dako; 1:100 dilution) followed by HRP-conjugated strep-
tavidin (LSAB+ kit). All stainings were visualised with DAB + substrate (Dako, Cat. K0690) 
as per the manufacturer’s instructions. 
2.4. Quantitation of Immunohistochemical Staining 
For analysis, stained slides were scanned at 40× magnification using the Aperio 
Scanscope XT instrument (Vista, CA, USA). PanCK+ and SOX9+ were quantitated using 
the “Positive Pixel Count” algorithm (Aperio ImageScope software) as previously pub-
lished [30]. Briefly, positively stained pixels were calculated as a percentage of total pixels, 
yielding % pixel positivity. For analysis of CD45 and F4/80 staining, ImageScope was used 
to evaluate 20 fields (20× magnification) per sample; these were saved as TIFF files and 
directly imported into inForm for analysis. Algorithms were created and verified accord-
ing to parameters and procedures outlined in Tables S1 and S2. 
2.5. LPC Cell Lines and Cell Culture 
The PIL2, PIL4 and BMOL LPC cell lines used in this study were isolated from the 
livers of mice placed on the CDE diet [11,31,32] and cultured in Williams’ E Medium, sup-
plemented as previously described [30]. Supplements were reduced to 2% fetal bovine 
serum (FBS), 10 ng/mL epidermal growth factor (EGF), 15 ng/mL insulin-like growth fac-
tor II (IGF-II) and 0.25 U/mL Humulin R for three consecutive passages prior to use. 
2.6. Isolation and Culture of Murine Bone Marrow Macrophages (BMMOs) 
BMMOs were isolated from C57BL/6J mice by flushing the femur and tibia with PBS. 
The bone marrow cells were resuspended in RPMI-1640 (Gibco, Paisley, U.K., Cat. 31870) 
containing 1% L-glutamine, 1% Pen/Strep, MEM, 1X NEAA, 1% pyruvate and 20% FBS 
and 20 ng/mL CSF-1. Cells were incubated for 10 days at 37 °C and 5% CO2 with medium 
change every 3–4 days. 
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2.7. RNA Extraction and Gene Expression Quantification 
Liver, LPC and BMMO samples were homogenised in QIAzol and phase-separated 
following the addition of chloroform and centrifugation at 12,000× g for 15 min. The aque-
ous (RNA) phase was extracted and added to an equal volume RNeasy Mini kit RLT 
buffer (QIAGEN, Valencia, CA, USA, Cat. 74104). Total RNA extraction then proceeded 
according to the RNeasy Mini Kit instructions. Reverse transcription of 5 µg total RNA 
was performed with Tetro Reverse Transcriptase according to manufacturer’s instructions 
(Bioline, Eveleigh, Australia). Quantitative RT-PCR was performed using the Light-
Cycler® 480 Probes Master kit (Roche) and primers (Table S3) with corresponding probes 
as determined using the Universal ProbeLibrary Assay Design Center. All results were 
normalised to the expression of the Taf4a or Gapdh housekeeping gene. 
2.8. Western Blotting and Protein Quantitation 
Prior to harvest, LPCs and BMMOs were serum-starved for 4 h. Afterwards, cells (5 
× 105 cells/well) were preincubated with 10 µM MVC for 30 min and/or 50 ng/mL recom-
binant murine CCL5 (R&D Systems, Lancater, CA, USA) for 15 min. Cellular proteins 
were extracted, and Western blot analysis was performed. Liver tissue and LPC lines were 
lysed in DISC Lysis Buffer (150 mM NaCl, 2 nM EDTA, 1% Triton-X, 10% glycerol, 20 mM 
Tris, pH 7.0) supplemented with 1X Complete Protease Inhibitor Cocktail (Roche Diag-
nostics, Castle Hill, Australia, Cat. 11697498001), 10 mM sodium fluoride, 2 mM sodium 
pyrophosphate, 1 mM sodium molybdate and 5 mM-glycerophosphate. Protein content 
of lysates was quantified using the Bradford Protein Assay (Bio-Rad, Gladesville, Aus-
tralia, Cat. 500-0006). Lysates (60 µg) were boiled in sample buffer (2% (w/v) sodium do-
decyl sulphate (SDS), 10% (v/v) glycerol, 62.5 mM Tris pH 6.8, 0.02% (w/v) bromophenol 
blue, with 1% (v/v) 2-mercapto ethanol) and separated by SDS polyacrylamide gel elec-
trophoresis. Electrophoresed proteins were transferred to Hybond C-extra membrane (GE 
Life Sciences, Buckinghamshire, U.K., Cat. RPN303E) using the wet-transfer method and 
Criterion blotter (Bio-Rad) at 110 V for 45 min at 4 °C in transfer buffer (25 mM Tris-base, 
192 mM glycine, 20% (v/v) methanol). Once transferred, the membranes were blocked us-
ing 5% (w/v) skim milk powder in Tris -buffered saline-Tween-20 (TBST; 25 mM Tris pH 
7.5, 150 mM NaCl, 0.1% (v/v) Tween-20) before blotting overnight with anti-E-cadherin 
(Cell Signaling Technology®, Danvers, MA Cat. 3195; 1:5000), anti-M2PK (Cell Signaling 
Technology®, Cat. 3198S; 1:1000), anti-CD133 (Abnova, Jhongli City, Taiwan, Cat. 
PAB12663; 1:1000), anti-GAPDH (Cell Signaling Technology®, Danvers, MA, USA, Cat. 
5174; 1:18,000), anti-CD68 (Biorad, Hercules, CA, USA Cat. MCA1957T; 1:1000), anti-YM1 
(R&D, Cat. AF2446; 0.2ug/mL), anti-pAKT (Cell Signaling Technology®, Cat. 4060; 1:1000), 
anti-pSTAT3 (Cell Signaling Technology®, Cat. 9145; 1:1000) and anti-pERK (Cell Signal-
ing Technology®, Cat. 4370; 1:1000) at 4 °C and anti-AKT (Cell Signaling Technology®, Cat. 
9272; 1:1000), anti-STAT3 (Cell Signaling Technology®, Cat. 9139; 1:1000) and anti-ERK 
(Cell Signaling Technology®, Danvers, MA, USA, Cat. 4695; 1:1000) at room temperature. 
HRP-linked secondary antibodies to rabbit (GE Life Sciences, Westborough, MA, USA, 
Cat. NA9340), goat (Jackson ImmunoResearch, Suffolk, U.K., Cat. 112-035-003) or mouse 
(GE Life Sciences, Westborough, MA, USA, Cat. NA9310) were used at a 1:5000 dilution. 
Whole blot images are shown in Supplementary Figure S10. 
2.9. Proliferation Assay 
LPCs were plated in 96-well plates at a cellular density of 2000 cells per well in 50 µL 
of medium, supplemented with 5% fetal bovine serum. The next day, cells were preincu-
bated with 10 µM Sorafenib, 1 µM MVC for 30 min and/or recombinant murine 50 ng/mL 
CCL5 (R&D Systems) for 15 minutes. With treatment, the total volume of each well was 
made up to 200 µL before assessment of growth using the CELLAVISTA instrument 
(SYNENTECH GmbH). Two cell confluency readings (ideally 12 h apart) were taken per 
day for at least 4 days or until cell growth plateaued. The confluency percentage for each 
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timepoint for each well was generated by the CELLAVISTA software and imported into 
an “XY” GraphPad Prism spreadsheet. The exponential growth phase of each well (as 
defined by data points that best fit an exponential growth equation) was used to deter-
mine doubling time (i.e., the time taken for the area occupied by cells to double). These 
doubling times were generated by GraphPad Prism after fitting the confluency data to an 
exponential growth equation. Average doubling times and statistics were then obtained 
by moving the data to a “column” spreadsheet within GraphPad Prism. Lower average 
doubling times reflect a more rapid proliferation. 
2.10. RNA-Seq 
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Hilden, Germany 
Cat. 74104) and quantitated using Qubit® RNA BR Assay Kit (Thermo Fisher Scientific, 
Rockford, IL, USA.) according to the manufacturer’s instructions. Sequencing libraries 
were generated from 1 µg of total RNA using the TruSeq Stranded mRNA HT Sample 
Prep Kit (Illumina, San Diego, CA, USA) and sequenced to a depth of ~20–30 million reads 
per sample using 50-cycle single-end reads. Reads were aligned to the mm10 mouse ref-
erence genome using Bowtie 2, and fragments per kilobase of transcript per million 
mapped reads (FPKM) were calculated using cuffnorm. 
2.11. Single-Nucleus RNA Sequencing (snRNA-Seq) 
Single-nucleus RNA sequencing analysis of Control, CDE and thioacetamide (TAA)-
treated mice for 21 days was conducted by Carlessi et al. as part of a liver single-nucleus 
transcriptomics study, yet to be published. Briefly, 40,748 nuclei from the three treatment 
groups combined were profiled using the 10× Chromium Single Cell 3′ v3 platform. Nuclei 
were prepared as in [33], loaded onto a 10× chip A and processed on the 10× Chromium 
controller. Libraries were prepared as per 10× Chromium Single Cell 3′ v3 workflow in-
structions and sequenced in an Illumina NovaSeq 6000 with S2 flow cells. Reads were 
mapped using Cell Ranger 2.1.1 with mm10-2.1.0 reference, and downstream quality con-
trol, dimensionality reduction, unsupervised clustering and differential expression anal-
yses were conducted on Seurat v3. Ten individual cell type clusters were identified and 
manually annotated using cell identity marker genes. The expression levels of Ccr5 were 
log2 transformed, then reported as mean ± standard error of the mean (SEM) across cell 
types and treatment groups. 
2.12. Measurement of Impedance-Based Wound Healing of Confluent BMMO Cultures 
Wound healing was determined in BMMOs using the electric cell-substrate imped-
ance sensing (ECIS) system (Applied Biophysics, Troy, NY, USA) as described previously 
[34]; 1.2 × 104 untreated or treated (10 µM MVC and/or 50 ng/mL CCL5) BMMOs were 
grown with 10% fetal bovine serum (FBS)-supplemented culture medium on ECIS elec-
trode arrays (8W1E). The impedance fluctuations of cell attachment and spread were con-
tinuously monitored. Impedance measurements were collected at 5 min intervals until 
confluence was achieved. At confluence, wounding of BMMOs was achieved using a 1400 
µA signal at 60 kHz for 20 s. Application of this field results in the death of the cells on 
the electrode and a rapid drop in impedance. Impedance then increases as cells migrate 
from the perimeter of the electrode inwards to replace killed cells. The slope of the imped-
ance measurement over time is proportional to the speed of cell migration. 
2.13. Transwell Migration Assay 
Cell migration assays were also performed using Transwells®. Twelve-well plates 
with 8 µm pore size inserts (Corning, NY, USA, Cat. 3422) were seeded with 5 x 104 
BMMOs in 200 µL of media without FBS ± MVC (10 uM) were added to the upper com-
partment. Five hundred microliters of DMEM without FBS containing 50 ng/mL CCL5 
was added to the lower compartment. BMMOs were incubated in Transwell plates at 37 
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°C and 5% CO2. After 24 h, the insert was taken out, and BMMOs on the lower side of the 
insert filter were quickly fixed in 5% glutaraldehyde (Sigma, St Louis, MO, USA.) for 10 
minutes then stained with 1% crystal violet (Sigma, St Louis, MO, USA) in 2% ethanol for 
20 min. Images of the lower side of the filter were recorded under a microscope (Leica 
CTR4000, Wetzlar, Germany). The extent of migration was determined by calculating 
membrane coverage using image thresholding in the ImageJ software (National Institutes 
of Health, Bethesda, ML, USA). 
2.14. β-Arrestin Recruitment 
Recruitment of β-arrestin-1 to human and mouse CCR5 (hCCR5 and mCCR5) in-
duced by human and mouse CCL5 chemokines (hCCL5 and mCCL5) was monitored by 
NanoLuc complementation assay (NanoBiT, Promega, Madison, WI, USA), as previously 
described [35–37]. Briefly, 5 × 106 HEK293T cells were seeded in 10 cm culture dishes and, 
24 h later, co-transfected with pNBe vectors encoding human or mouse CCR5 C-termi-
nally fused to SmBiT and β-arrestin-1 N-terminally fused to LgBiT. Twenty-four hours 
post transfection cells were harvested, incubated for 25 minutes at 37 °C with 200-fold 
diluted Nano-Glo Live Cell substrate and distributed into white 96-well plates (5 × 104 
cells per well). Cells were then treated with MVC for 20 min at room temperature at con-
centrations ranging from 0.05 nM to 1.11 µM for hCCR5 and from 4.57 nM to 50 µM for 
mCCR5 then stimulated with human or mouse CCL5 (5 nM). β-arrestin recruitment to 
hCCR5 and mCCR5 was evaluated by measuring bioluminescence with a Mithras LB940 
luminometer (Berthold Technologies, Bad Wildbad, Germany). 
2.15. Statistical Analyses 
Data are presented as means and standard errors of the means (SEM). Statistical anal-
yses were performed using Mann–Whitney U-test unless stated otherwise. For the imped-
ance assay, the growth phases were fitted by simple linear regression with the test for 
significant differences in slopes selected. All statistics were performed in GraphPad Prism 
5 software, San Diego, CA, USA. 
3. Results 
3.1. Maraviroc Inhibited Human and Mouse CCR5 
Maraviroc (MVC) is a drug designed to block the entry of HIV into human cells, and 
its interaction with human CCR5 is well established [38], but whether it affects mouse 
CCR5 has not been formally demonstrated. Binding of ligand to CCR5 results in β-arres-
tin-1 recruitment to the receptor. We showed that β-arrestin-1 recruitment was inhibited 
by MVC, demonstrating that it inhibited mouse CCR5. However, inhibition of mouse 
CCR5 by MVC (IC50 1.9 µM) was 76 times less effective than its inhibition of human CCR5 
(IC50 25 nM) (Figure S1). 
3.2. MVC Treatment Significantly Reduced CDE-Diet-Induced Liver Progenitor Cell 
Proliferation 
It has been reported that LPCs express CCR5 [21]. Therefore we explored the possi-
bility that MVC (by inhibiting CCR5) could reduce LPC expansion and subsequent HCC 
development. In control and MVC-treated mice, PanCK+ cells were restricted to a single 
layer lining the bile ducts and constituted 0.20 and 0.14% of total pixels, respectively  
(Figure 1A,B,E). In contrast, CDE diet administration induced large numbers of non-duc-
tal, PanCK+ LPCs, which constituted 3.3% of the total pixels—a 1553% increase (p = 0.0286) 
(Figure 1C,E). Co-administering MVC with the CDE diet significantly (p = 0.0081) reduced 
the LPC response by 54%, to 1.5% of total pixels (Figure 1D,E). The LPC response of each 
individual liver, as judged by PanCK levels, positively correlated with the extent of liver 
damage indicated by serum alanine aminotransferase (ALT) activity (r2 = 0.69; Figure S2). 




Figure 1. PanCK-positive cell numbers are reduced by MVC in CDE liver. (A–D) Representative images of histological 
sections stained with PanCK antibody, from 16-wk control (A), MVC (B), CDE (C) and CDE+MVC (D) animal groups. (E) 
Quantitation of PanCK staining by pixel positivity. Bars represent means + SEM for n = 4, 8, 4 and 8 in the control, MVC, 
CDE and CDE+MVC groups, respectively. * p < 0.05 compared to control. ## p < 0.01 compared to CDE group. Scale bars 
represent 50 µm. 
The extent of LPC abundance in the liver was also gauged by quantification of mRNA 
levels of LPC-associated markers (Figure 2). Ck19 is commonly used to identify LPCs, and 
its expression increased by 3759% in the CDE diet compared to controls. MVC treatment 
reduced Ck19 expression by 48% when compared with the CDE group (Figure 2A). LPCs 
possess stem-cell-like properties, and thus the expression of stem-cell-associated markers 
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such as Cd133 (Figure 2B), Sox9 (Figure 2C), Ncam1 (Figure 2D), Cd24a (Figure 2E) and 
M2pk (Figure 2F) was also evaluated. These markers were significantly increased by 
11,894%, 881%, 6216%, 2544% and 1093%, respectively, in mice subjected to the CDE diet 
relative to control levels. Expression values were decreased by 71%, 67%, 66%, 82% and 
71% when mice on the CDE diet were also treated with MVC. When evaluated by im-
munohistochemistry (IHC), SOX9 pixel positivity increased by 9621% in the CDE diet rel-
ative to the control. Treatment with MVC reduced SOX9 pixel positivity by 53% in the 
CDE+MVC group relative to the CDE diet group (Figure S3). No significant differences 
were observed between the livers of the control diet and the control + MVC diet with 
respect to all markers assessed. The expression of these genes was compared with LPC 
abundance, as assessed by PanCK staining quantitation, obtaining a positive correlation 
(r2 = 0.58–0.82; Figure S4). 
 
Figure 2. The mRNA expression of LPC markers is attenuated by MVC in CDE liver. (A–F) Quanti-
tative PCR was performed using cDNA from the livers of animals in the 16-wk control, MVC, CDE, 
and CDE+MVC groups to amplify genes associated with oval cells. Expression levels are shown 
relative to the housekeeping gene, TaF4a. Bars represent means + SEM for 7 animals per group. * p 
< 0.05, *** p < 0.001 compared to ctrl. # p <0 .05, ## p < 0.01 compared to CDE group. 
The CD133 and M2PK markers were further assessed by Western blotting to confirm 
their protein abundance was increased by CDE, and this was attenuated by MVC (Figure 
3A). Quantification of the protein bands (Figure 3A) showed that, compared to controls, 
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CDE administration, on average, increased the abundance of these LPC-associated pro-
teins by 1792% and 628%, respectively. Co-administration of MVC reduced expression of 
these markers by 74% and 53%, respectively, in the CDE+MVC group relative to the CDE 
diet group (Figure 3B,C). Taken together, the increase in LPC number in response to CDE 
diet administration was reduced when MVC was co-administered, as determined by im-
munohistochemistry, LPC-specific mRNA expression and protein abundance. 
 
Figure 3. The protein expression of LPC markers is attenuated by MVC in CDE liver. (A) Protein 
lysates from livers of two mice fed either control, CDE, MVC or CDE+MVC diets for 16 weeks were 
immunoblotted and labelled for CD133, M2PK and the loading control GAPDH. (B,C) Abundance 
of CD133 and M2PK relative to GAPDH, as calculated through densitometry performed on the im-
ages in (A). 
3.3. MVC Reduced CDE-Induced Phosphorylation of AKT and STAT3 
Proliferation and migration of activated LPCs are considered key events in hepatic 
regeneration, and these processes are mediated by phosphorylation of AKT, STAT3 and 
ERK [39,40]. These pathways are downstream of CCR5 signalling and as such were inves-
tigated as a potential mechanism for the MVC-induced LPC attenuation. The amount of 
phosphoAKT, phosphoSTAT3 and phosphoERK (pAKT, pSTAT3 and ERK) relative to 
their total protein levels was examined in lysates from each of the four experimental 
groups (control, MVC, CDE and CDE+MVC). There was a trend toward increased phos-
phorylated AKT; which was enhanced (283%) in livers from CDE mice relative to controls 
(p = 0.057) and was attenuated (32% reduction) in CDE+MVC-treated mice relative to CDE 
levels (p = 0.028) (Figure 4E,F). Phosphorylated STAT3 was increased (221%) in CDE livers 
relative to controls (p = 0.057) and was diminished (45% reduction) in the CDE+MVC 
group compared to CDE levels (p = 0.028) (Figure 4A,B). No significant change was ob-
served for pERK (Figure 4C,D). These signalling changes were accompanied by global 
proteostatic derangements in which MVC reverted multiple CDE-induced changes at pro-
teome level, modulating wide-ranging biological functions such as amino acid, fatty acid 
and carbohydrate metabolism and detoxification (Figure S7). Given these results, pAKT, 
pSTAT3 and pERK levels were examined in LPCs and BMMOs following treatment with 
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murine recombinant CCL5, in the presence and absence of MVC. Treatments did not sig-
nificantly alter pAKT and pSTAT3, in either cell type, or pERK levels in BMMOs (Figures 
S5 and S6). Whilst CCL5 treatment increased pERK expression in LPCs, MVC did not ab-
rogate this response, indicating that MVC had little to no effect on these signalling path-
ways in these cells. 
 
Figure 4. pSTAT3 and pAKT expression is attenuated by MVC in CDE liver. (A,C,E) protein lysates 
from livers of mice fed Ctrl, CDE, MVC or CDE+MVC diets for 16 weeks were immunoblotted and 
labelled for phosphorylated (A) STAT3, (C) pERK, (E) pAKT and their loading controls; total STAT3, 
ERK and AKT, respectively. (B,D,F) the abundance of each phosphorylated protein relative to its 
control was calculated through densitometry performed on the blot images. Bars represent means + 
SEM for n = 3 mice in the Ctrl and MVC groups and n = 4 in the CDE and CDE+MVC groups. # p < 
0.05 compared to CDE group. 
3.4. CCL5 and MVC Did Not Alter Proliferation of LPC Lines 
To further investigate whether CCL5 and/or MVC directly affect their growth, LPCs 
were treated with CCL5 and/or MVC, and their proliferation was measured using image-
based confluency determination. Under the conditions tested, cell growth rates were un-
changed compared to untreated cultures (Figure S8A). In contrast, the doubling time of 
LPCs increased 2.5-fold when treated with Sorafenib as a positive control (p = 0.0313; Fig-
ure S8B). 
3.5. Ccr5 Was Expressed by CDE Liver and Macrophages but Not by LPCs 
Treatment with MVC clearly attenuated the LPC response, but LPCs did not display 
changes in AKT, STAT3 or ERK signalling in response to MVC (Figure S5). As such, we 
tested the expression of the MVC receptor, Ccr5, in these cells, hepatocytes and liver ly-
sates. By RNA-Seq (Figure 5A), RT-PCR (Figure 5B) and snRNA-Seq (Figure 5C), LPCs 
expressed no or very low levels of Ccr5. Accordingly, it was likely that MVC was working 
through an intermediary to affect the LPC response. Primary hepatocytes expressed only 
a small fraction of the total Ccr5 expressed in liver lysates (Figure 5A), indicating a non-
parenchymal cell source was largely responsible for the expression of this receptor, par-
ticularly in the CDE diet which is known to be inflammatory. Indeed, we observed a slight 
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1.3× increase in Ccr5 expression in the CDE diet relative to normal liver (Figure S9). Mac-
rophages are known to be intricately involved with the LPC response; thus we tested Ccr5 
expression levels in BMMOs. The BMMOs expressed Ccr5 at far greater levels than LPC 
cell lines or liver lysates (Figure 5B) indicating that they could be the intermediary result-
ing in attenuation of the LPC response. 
 
Figure 5. Inflammatory cells express high levels of Ccr5, and LPCs do not. (A) Expression of Ccr5 was examined by RNA-
Seq in primary LPCs, LPC lines, primary and cultured hepatocytes and whole normal murine liver. Expression values are 
provided as fragments per kilobase of transcript per million mapped reads (FPKM). A dotted threshold was placed at 
FPKM = 0.25 to indicate the level above which a gene may be considered actively expressed. Bars represent means + SEM 
n = 3, 12, 3, 3 and 3 for primary LPC cultures, LPC lines, primary hepatocyte cultures, cultured hepatocytes and liver tissue, 
respectively. (B) RT-PCR was performed to amplify Ccr5 and the GAPDH loading control, using cDNA from BMMOs, 
LPCs and murine liver. (C) Single-cell Ccr5 expression analysed by snRNA-Seq in Control, CDE-treated and TAA-treated 
livers. Ten major hepatic cell types were identified and log2-transformed Ccr5 expression reported for every cell type in 
each treatment group. Bars represent mean ± SEM. Myeloid (macrophages and monocytes), pDCs (plasmacytoid dendritic 
cells), T/NK (T cells and natural killer cells), HSCs (hepatic stellate cells), Cholangio (cholangiocytes), LPCs (liver progen-
itor cells). 
Moreover, by snRNA-Seq we further investigated Ccr5 expression in liver cell types. 
Ccr5 was only detected in reliable amounts in myeloid cells (including different types of 
macrophages, monocytes and DCs), while T and NK cells also expressed Ccr5 but in 
smaller amounts. All other cell types in the liver, such as LPCs, did not show consistent 
Ccr5 expression levels (Figure 5C). 
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3.6. MVC Treatment Significantly Reduced the Inflammatory Response to the CDE Diet 
As the CDE diet induces an inflammatory response [24], the number of CD45+ in-
flammatory cells and F4/80+ macrophages was examined in CDE-diet (Figure 6E,F) and 
CDE+MVC-treated (Figure 6G,H) liver sections. The number of CD45+ cells in the livers 
of CDE-fed mice was significantly reduced by MVC treatment (p = 0.041) (Figure 6I). There 
was a trend towards reduction in the number of F4/80-positive cells by MVC, although 
their difference did not reach statistical significance (p = 0.20) (Figure 6J). 
 
Figure 6. Resident and infiltrating inflammatory cell numbers are attenuated by MVC in CDE liver. 
Representative images of histological sections stained with CD45 (A,C,E,G) or F4/80 (B,D,F,H) in 
Ctrl (A,B), MVC (C,D), 16-wk CDE (E,F) and CDE+MVC (G,H) animal groups. (I,J) Quantitation of 
CD45+ and F4/80+ cell numbers per field of view by the inForm software. Bars represent the mean 
± SEM for 8, 11, 6 and 14 animals in the Ctrl, MVC, CDE and CDE+MVC groups, respectively. * p < 
0.05, *** p < 0.001, compared to Ctrl. # p < 0.05 compared to CDE group. The scale bar represents 50 µm. 
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3.7. MVC-Treated Macrophages Exhibited Reduced Migration 
Migration of BMMOs using an alternate impedance-based wound healing assay was 
also inhibited (Figure 7C; p < 0.0001). CCL5 showed better wound healing capabilities 
based on more rapid wound closure (migration, slopes of the curves) in comparison to the 
MVC-treated wells, demonstrating that MVC was capable of influencing macrophage re-
cruitment. 
 
Figure 7. MVC reduces macrophage migration in vitro. (A) Transwell migration assay. BMMOs 
were seeded in the upper chamber of the Transwell ± MVC, and medium without serum but con-
taining mCCL5 was placed in the well. Images display migrated crystal-violet-stained cells follow-
ing a 24 h migration. Representative images are shown at 10x objective lens magnification. (B) Quan-
titation of the migration images by image thresholding. The bars represent the mean + SEM for n = 
3, 4, 4 and 4 for the Ctrl, MVC, CCL5 and CCL5+MVC groups, respectively. (C) Resistance/imped-
ance over time as measured by the cell migration after electric wounding (ECIS) apparatus. Re-
sistance is proportional to wound closure, representative of cell migration. Cells were stimulated (± 
MVC and CCL5). Data shown are results from 4 different cell cultures. **** p < 0.0001 between Ctrl 
and CCL5, # p < 0.05, #### p < 0.0001 between CCL5 and CCL5+MVC. 
3.8. MVC Modified Macrophage Polarization Induced by CDE 
In many tumours, infiltrating macrophages are predominantly the “alternative” M2-
like type, providing an immunosuppressive environment that encourages tumour growth 
[41]. Given the anti-tumour effect of MVC, its effect on polarization was investigated with 
respect to the TAM markers CD68 and YM-1. All TAMs, including both the M1-like and 
M2-like subtypes, can be identified and quantified by CD68 immunoreactivity [42], 
whereas YM-1 marks M2 macrophages exclusively [43]. In comparison with controls, CDE 
administration trended towards increased CD68 and YM1 abundance by 164% and 64% 
(p = 0.057), respectively, suggesting a diet-induced transition to the M2-like polarity. Ex-
pression of these markers was 91% and 98% lower (p = 0.028), respectively, in mice that 
were treated with CDE+MVC when compared with the CDE group (Figure 8B,C). The 
magnitude of these decreases is much higher than the reduction in macrophage numbers 
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observed earlier (Figure 7). As such, these changes signify that MVC actively reversed the 
CDE-induced transition from the M1-like to the M2-like macrophage phenotype. 
 
Figure 8. MVC diminishes CDE-induced M2 polarization of macrophages. (A) Protein lysates from livers of mice fed 
Control, CDE, MVC and CDE+MVC diets for 16 weeks were immunoblotted and labelled for CD68, YM1 and the loading 
control GAPDH. (B,C) Abundance of each protein relative to its control, was calculated through densitometry performed 
on the images. Bars represent means + SEM for n = 3 mice in the Ctrl and MVC groups and n = 4 in the CDE and CDE+MVC 
groups. # p < 0.05 compared to CDE group. 
4. Discussion 
Liver cancer is a significant cause of mortality worldwide, and it will acquire in-
creased importance as lifestyle factors that cause liver disease, such as obesity and alcohol 
consumption, continue to rise [44,45]. Advances in our knowledge of the hepatocarcino-
genic process are hampered by a paucity of animal models that mimic the human condi-
tion. This, together with the inability to identify early stages of HCC in humans, has re-
sulted in a poor understanding of the target cell for transformation and the molecular 
mechanisms that underpin the process. 
The murine CDE diet model is a fat-induced chronic liver disease model that displays 
the hallmarks of liver inflammation, fibrosis and ultimately cancer that is associated with 
HCC, thus recapitulating the process that develops in humans. The consistent theme of 
our studies based on this model is that a ductular proliferation response is an early event 
that generates a population of liver progenitor cells, and their abundance correlates with 
HCC development. In studies where the LPC response is attenuated by reducing the in-
flammatory response—especially in transgenic mice with a deficient immune system such 
as in IL6R, TNFR or FN14 knockout mice—the development of HCC is commensurately 
reduced [24,26]. In humans, the severity of liver-cancer-causing diseases positively corre-
lates with LPC numbers [5], and LPC markers have accurately predicted short-term mor-
tality in patients with alcoholic hepatitis [6]. From a clinical translation perspective, we 
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have previously demonstrated that the commercially available CCR5 antagonist, MVC, 
was able to reduce HCC development in the CDE model by 72%. No significant difference 
was observed for any parameter when comparing animals that received a normal diet in 
the presence or absence of MVC treatment [28]. This confirms that the drug is fairly safe. 
The mechanism by which MVC reduces HCC development is not known. This knowledge 
would underpin strategies to reposition this drug for use in patients with liver pathologies 
to reduce their progression to HCC. 
There is evidence that CCR5 promotes the induction and maintenance of liver inflam-
mation in CDE-diet-treated mice as it facilitates the recruitment of immune cells into the 
liver [21]. The involvement of the CCR5 ligand, CCL5, in cancer and specifically in HCC 
has been extensively studied. The majority of studies claim a tumour-promoting role for 
CCL5 [46]. CCL5 levels were highly correlated with disease progression in advanced HCC 
[18]. Studies attenuating the activities or expression of CCL5 by MVC [28] and in mouse 
models of HCC [18,47] indicate that CCL5 signalling is directly responsible for HCC de-
velopment. Furthermore, overexpression of CCL5 promotes tumour growth and disease 
progression [48]. 
The mechanism by which the CDE diet induces liver fibrosis and HCC involves dam-
age to the liver parenchyma with a simultaneous blockade of hepatocyte proliferation [49]. 
This, in turn, induces the production of a large number of LPCs which remodel the hepatic 
parenchyma [32]. It has been shown that CCL5 facilitates chemotaxis of liver progenitor 
(oval) cells [21] probably through binding to CCR1 and CCR3, which may explain their 
abundance in the liver of rodents that had received the CDE diet. Moreover, oval cells 
may transform into cancer stem cells and directly contribute to HCC [50]. Thus, as MVC 
acts as a CCR5 antagonist and drastically decreases tumour incidence, it may modulate 
the LPC response and prevent development of HCC. 
Given the association between HCC development and LPC abundance, we examined 
the ability of MVC to modulate the LPC response. We showed MVC reduces the LPC 
response based on quantitation of PanCK- and SOX9-positive cells. Alternative ap-
proaches to quantify the LPC response based on gene expression for a range of LPC-spe-
cific mRNAs, as well as their respective protein abundance, confirmed the staining results. 
By these criteria, the CDE diet increased the LPC response by 10- to 120-fold above control 
diet levels depending on the marker examined. Notwithstanding the large range of re-
sponses, a reproducible and consistent decrease in the LPC response of between 54 and 
82% was observed when MVC was co-administered with the CDE diet. 
As MVC appeared to modulate LPC abundance, we sought to define its effect on 
proliferation. Phosphorylation of STAT3, ERK and AKT is downstream of CCR5 signal-
ling and intimately involved in cell proliferation and hepatic regeneration [39,40], sug-
gesting that modified pAKT- signalling may play a role in attenuating the LPC response. 
The levels of pAKT and pSTAT3 trended higher in CDE liver and diminished significantly 
by MVC administration, indicating CCR5 mediates the LPC response and MVC attenuates 
it. Surprisingly, changes in pAKT and pSTAT3 were not detected in LPCs or BMMOs, nor 
did CCL5 treatment alter their proliferation. Collectively these data indicate that MVC 
modulates active pAKT and pSTAT3 signalling in the CDE diet; however, these prolifer-
ative effects are not directly achieved within the LPC or BMMO compartment. 
It has been reported that LPCs express CCR5 [21] and they increase the number of 
HSCs through an epithelial–mesenchymal transition process, thus contributing to liver 
fibrosis [51]. In contrast to these findings, we were unable to detect CCR5 expression in 
freshly isolated primary LPC cultures, or LPC cell lines, using RNA-seq and RT-PCR. 
High levels of CCR5 expression were detected in control liver; however, considerably 
lower expression was detected in primary hepatocytes. These results indicate that neither 
hepatocytes nor LPCs are the main contributors of CCR5 expression in the CDE liver. 
Macrophages are crucial drivers of tumour progression, and they express CCR5 [52], con-
sistent with our finding that BMMOs express high levels of CCR5. 
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The expression of CCR5 was also studied by IHC in liver sections [28] of CDE and 
CDE+MVC groups. In animals receiving the CDE diet, CCR5 expression was upregulated 
around portal tracks, mostly in inflammatory cells such as macrophages and HSCs. More-
over, our snRNA-seq data show that only inflammatory cells display CCR5. The snRNA-
Seq data show that cells with the expression profile of LPCs do not express CCR5 mRNA 
(or levels are not detectable).  
MVC inhibits T-cell proliferation [53]. It also inhibits T-cell chemotaxis toward their 
cognate ligands [54] and reduces the regulatory T-cell frequency [55], as well as leukocyte 
trafficking to the gut [56], cancer-associated fibroblasts [57] and macrophage infiltration 
[58]. It has also been reported that MVC decreases chemotactic activity of macrophages 
[59,60]. Moreover, MVC can decrease AKT signalling as demonstrated in both RAW 264.7 
cells and bone-marrow-derived macrophages [61]. Therefore, MVC might indirectly at-
tenuate the LPC response by affecting other cell types, particularly, macrophages. Con-
sistent with this proposition, MVC-treated BMMOs showed lower migration capabilities 
in comparison with CCL5-treated cells. This mechanism is a likely explanation for the re-
duced liver tumour formation/progression elicited by MVC previously reported [28].  
The inflammatory response is a major component of the CDE dietary model [62]. Our 
finding that CCR5 is expressed in whole liver and is increased in CDE-treated liver sug-
gests that liver inflammatory cells are the main source of the receptor. HSC activation 
induced by the CDE diet can be pro-inflammatory, supporting the development of HCC 
[63]. Our previous study demonstrated that MVC can modulate HSC activity and reduce 
the levels of proinflammatory cytokines such as IL-6, IL-12, TGF-β and MMP9, suggesting 
a reduced recruitment of immune cells [28]. In this study, we confirmed the activity of 
CCR5 on immune cell recruitment by demonstrating that infiltrating CD45+ decreased in 
number in response to MVC. 
Macrophage subpopulations are either classically activated (M1; pro-inflamma-
tory/tumouricidal) or alternatively activated (M2; specialised to suppress inflammation) 
[64]. Tumour-associated macrophages (TAMs) are a heterogeneous population of myeloid 
cells that contribute to immunosuppression, favouring the establishment and persistence 
of solid tumours as well as metastatic dissemination. Like regular macrophages, TAMs 
can be classified on an M1-to-M2 spectrum, expressing variable levels of cytokines. Tissue 
microenvironment (TME) ligands, including CCL5, recruit TAMs to the TME [65]. Mono-
cytes from peripheral blood are recruited into the TME and differentiate into TAMs in 
response to chemokines, including CCL5 (secreted by M2-like macrophages), and growth 
factors produced by stromal and tumour cells [64]. By secreting CCL5, M2-TAMs may 
activate signal STAT3 leading to enhanced cancer cell proliferation and invasion/metasta-
sis formation. Upon secreting CCL5, tumour cells recruit CCR5-expressing TAMs [66,67]. 
Concordantly, Halama et al. [68] found that blocking the CCR5/CCL5 axis with MVC 
in functional organoids derived from metastatic colorectal cancer (CRC) patients induced 
macrophage repolarization with anti-tumoural effects. Immunosuppressive M2-tumour-
associated macrophages (TAMs) can be reprogrammed to an anti-tumoural M1-TAM sub-
type by targeting the CCR5/CCL5 axis [69]. Consistently, a significant positive correlation 
was found between the expression of CCL5 and CD68 in gastric cancer tissues. High levels 
of CCL5 and CD68 are associated with tumour size, degree of tumour invasion, lymphatic 
metastasis and pathological grading [70,71]. 
We demonstrated that MCV reduces liver immunosuppressive M2-TAM markers 
(CD68 and YM1). Therefore, we suggest that MVC, by reducing the binding of CCL5 to 
CCR5, is able to inhibit TAM promotion of tumour cell proliferation, invasion and metas-
tasis. Targeting the CCR5/CCL5 axis with MVC reprograms immunosuppressive M2-
TAMs to anti-tumoural M1-TAMs, reinvigorating anti-tumour immunity. Thus, MVC, 
which is capable of disrupting CCL5/CCR5 interaction, may represent a new potential 
therapeutic option to counteract TAM-induced tumourigenesis. The inhibition of CCL5 
secretion by cancer cells or by the TME may represent an additional avenue to counteract 
liver tumour progression. 




MVC attenuates the development of HCC in the mouse CDE model. It affects both 
the incidence of HCC and the size of tumours [28]. We show that LPCs themselves do not 
express CCR5, and thus MVC does not attenuate the LPC response by direct action on 
these cells. Instead, its action is likely mediated by its ability to temper liver inflammation, 
which drives the LPC response. The anti-tumorigenic effect of MVC is two-fold. First it 
attenuates the LPC response and second, it reduces the pro-carcinogenic state of the mac-
rophages by reducing those with an M2 phenotype. As MVC is an approved drug for 
treating HIV patients, this study suggests that it may be re-purposed for reducing the 
progression of HCC in chronic inflammatory liver pathologies such as alcoholic liver dis-
ease, NAFLD, HBV and HCV, which show high numbers of LPCs, and where the LPC 
response or signature correlates with disease severity and prognosis [5]. 
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